Morgan Stanley analyst Erin Wright downgraded Elevance Health (ELV) to Equal Weight from Overweight with a price target of $388, down from $551. Year-to-date enterprise medical loss ratio has come in higher than expectations, in “no small part” due to the acuity-rate mismatch dynamic that is impacting Managed Medicaid players, notes the analyst, who sees continuing cost trend headwinds into 2025. With uncertainty around the timing of normalization and incremental pressure in Medicare Advantage, the firm believes “it is prudent to step back until proof points begin to come in throughout 2025,” the analyst tells investors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Lawmakers seek to break up PBMs from health insurers, WSJ reports
- Elevance Health price target lowered to $458 from $529 at Jefferies
- Molina Healthcare price target lowered to $312 from $348 at Jefferies
- CEO killing, rage over insurance pushes UnitedHealth into crisis, Bloomberg says
- Insurers collected billions in premiums from Medicare for veterans, WSJ says